The effect of absorption enhancers on the initial degradation kinetics of insulin by α-chymotrypsin
The effect of absorption enhancers on the initial degradation kinetics of insulin by α-chymotrypsin
复制标题
DOI:
10.1016/s0378-5173(01)00595-6
复制
发表时间:
2001-04-17
影响因子:
5.8
通讯作者:
Aboul-Enein, HY
中科院分区:
文献类型:
--
作者:
Radwan, MA;Aboul-Enein, HY
The goal of this investigation was to establish a fast method to screen various insulin absorption enhancers by following their effect on the initial kinetics of insulin incubated with alpha -chymotrypsin at 37 degreesC. A simple, sensitive and reproducible reversed phase high performance liquid chromatography (HPLC) method has been developed to carry out this goal. Linear responses (r > 0.999) were observed over the range of 0.4-4 U/ml for insulin. There was no significant difference (P < 0.05) between inter- and intra-day studies for insulin. The mean relative standard deviations (RSD%) of the results of within-day precision and accuracy of insulin were < 12%. The assay was sensitive to detect the existence of any metabolite due to the addition of any absorption enhancers, even if it was not seen with insulin alone. Three metabolites (A-C) were detected only when insulin was incubated with alpha -chymotrypsin at 37 degreesC. Metabolite D was observed when either glycocholic acid (0.5, 1%) or taurochenodeoxycholate (0.5, 1%) was incubated with insulin in the absence of alpha -chymotrypsin at 37 degreesC. The compounds that significantly increased insulin T-50% were glycyrrhizic acid (0.5%) > deoxycholic acid (1%) > deoxycholic acid (0.5%) > glycyrrhizic acid (1%) > cholic acid (0.5, 1%). Capric acid (0.5%), hydroxypropyl-alpha -cyclodextrin (0.5, 1%) and dimethyl-alpha -cyclodextrin (0.5, 1, 5%) did not significantly affect insulin T-50%. The bile salts increased insulin T-50% in this order: deoxycholate > cholate > glycocholate > taurocholate > taurodeoxycholate > taurochenodeoxycholate > glycodeoxycholate. The results obtained would support the feasibility of utilizing such method for screening any compound incorporated in insulin formulation. These compounds should be used in the minimum possible concentration to avoid or minimize insulin degradation. (C) 2001 Elsevier Science B.V. All rights reserved.